Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.

Abstract

BACKGROUND Deferasirox (DFX) is a novel iron chelator that has been shown to have similar efficacy and safety compared with deferoxamine (DFO) in patients with β-thalassemia. The aim of this study was to determine the cost utility of DFX versus DFO in β-thalassemia major patients from Iran's society perspective. STUDY DESIGN AND METHODS A Markov model has… (More)
DOI: 10.1111/trf.12024

Topics

Cite this paper

@article{Keshtkaran2013CostutilityAO, title={Cost-utility analysis of oral deferasirox versus infusional deferoxamine in transfusion-dependent β-thalassemia patients.}, author={Ali Naghi Keshtkaran and Mehdi Javanbakht and Sedigheh Salavati and Atefeh Mashayekhi and Mehrbod Karimi and Bijan Nuri}, journal={Transfusion}, year={2013}, volume={53 8}, pages={1722-9} }